Pharma companies to benefit from domestic demand in Q2 results

Pharma companies are likely to gain from domestic healthcare demand in the upcoming Q2 results despite weak export cues to the United States. The domestic market is expected to support performance as companies strengthen manufacturing capabilities.

Market experts say the US export business may decline due to lower sales, but domestic demand and CDMO growth will help. The US has exempted some speciality drugs from India from a 100% import duty rate, which may provide relief for eligible Indian drugmakers.